FDA Clearance Tracker · P170011-S049
Impella RP, Impella RP with Smart Assist, Impella $.0/LD
Last checked: Nov 20, 2026Latest source record: Apr 27, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Apr 27, 2023
Approved
Time to decision
30 days
Received Mar 28, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170011-S049
- Device name
- Impella RP, Impella RP with Smart Assist, Impella $.0/LD
- Applicant
- Abiomed, Inc.
- Applicant location
- Danvers, MA
- Received
- Mar 28, 2023
- Decided
- Apr 27, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P170011
Device type
- Device class
- Class III
- Regulation
- 21 CFR 870.4360
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the Impella Real-World Surveillance of patients using Sodium Bicarbonate.
Source documents
Other decisions for Abiomed, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252766 · Decided Oct 8, 2025 · 40 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.